Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2012-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s10549-011-1588-xPMID 21614566
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1)

  2009cited by this paper
• Genome-wide association study identifies a novel breast cancer susceptibility locus at 6q25.1

  2009cited by this paper
• Recent advances in systemic therapy. New diagnostics and biological predictors of outcome in early breast cancer

  2009cited by this paper
• Gene-expression signatures in breast cancer.

  2009cited by this paper
• Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2

  2009cited by this paper
• Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits

  2008cited by this paper
• PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene

  2007cited by this paper
• Ten genes for inherited breast cancer.

  2007cited by this paper
• A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer

  2007cited by this paper
• Genome-wide association study identifies novel breast cancer susceptibility loci

  2007cited by this paper
• Patterns of somatic mutation in human cancer genomes

  2007cited by this paper
• Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor–positive breast cancer

  2007cited by this paper
• Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.

  2006cited by this paper
• Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines

  2006cited by this paper
• X chromosomal abnormalities in basal-like human breast cancer.

  2006cited by this paper
• Oncogenic pathway signatures in human cancers as a guide to targeted therapies

  2006cited by this paper
• Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles

  2006cited by this paper
• Concordance among gene-expression-based predictors for breast cancer.

  2006cited by this paper
• Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.

  2006cited by this paper
• ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles

  2006cited by this paper
• The CHEK2 gene and inherited breast cancer susceptibility

  2006cited by this paper
• Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.

  2006cited by this paper
• A genome wide linkage search for breast cancer susceptibility genes

  2006cited by this paper
• Genetic regulators of large-scale transcriptional signatures in cancer

  2006cited by this paper
• An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.

  2005cited by this paper
• Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.

  2005cited by this paper
• Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling.

  2005cited by this paper
• Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant

  2004cited by this paper
• A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

  2004cited by this paper
• Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells.

  2004cited by this paper
• CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies.

  2004cited by this paper
• The Genetic Epidemiology of Breast Cancer Genes

  2004cited by this paper
• A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.

  2004cited by this paper
• Integrated global profiling of cancer

  2004cited by this paper
• Establishment of histone h3 methylation on the inactive X chromosome requires transient recruitment of Eed-Enx1 polycomb group complexes.

  2003cited by this paper
• Gene expression predictors of breast cancer outcomes.

  2003cited by this paper
• The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype.

  2003cited by this paper
• Repeated observation of breast tumor subtypes in independent gene expression data sets

  2003cited by this paper
• The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.

  2003cited by this paper
• Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer.

  2003cited by this paper
• Breast cancer classification and prognosis based on gene expression profiles from a population-based study

  2003cited by this paper
• Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer.

  2003cited by this paper
• RecQ helicases: caretakers of the genome

  2003cited by this paper
• A molecular signature of metastasis in primary solid tumors

  2003cited by this paper
• Gene expression profiling predicts clinical outcome of breast cancer

  2002cited by this paper
• BRCA1 supports XIST RNA concentration on the inactive X chromosome.

  2002cited by this paper
• Methods for assessing reproducibility of clustering patterns observed in analyses of microarray data

  2002cited by this paper
• Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations

  2002cited by this paper
• A gene-expression signature as a predictor of survival in breast cancer.

  2002cited by this paper
• A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.

  2002cited by this paper
• The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.

  2002cited by this paper
• Identification of high risk breast-cancer patients by gene expression profiling.

  2002cited by this paper
• Breast cancer susceptibility-A new look at an old model.

  2002cited by this paper
• Imprinted X inactivation maintained by a mouse Polycomb group gene

  2001cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001cited by this paper
• Chk2 kinase — a busy messenger

  2001cited by this paper
• Gene-expression profiles in hereditary breast cancer.

  2001cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper
• The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites.

  2000cited by this paper
• The DNA damage response: putting checkpoints in perspective

  2000cited by this paper
• DNA damage-induced activation of p53 by the checkpoint kinase Chk2.

  2000cited by this paper
• Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53.

  2000cited by this paper
• hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response

  2000cited by this paper
• Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks.

  1999cited by this paper
• Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations.

  1999cited by this paper
• Mutations in RECQL4 cause a subset of cases of Rothmund-Thomson syndrome

  1999cited by this paper
• Is TP53 dysfunction required for BRCA1-associated carcinogenesis?

  1999cited by this paper
• Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1.

  1998cited by this paper
• p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours

  1998cited by this paper
• p53 mutations in BRCA1-associated familial breast cancer.

  1997cited by this paper
• The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds

  1996cited by this paper
• Positional Cloning of the Werner's Syndrome Gene

  1996cited by this paper
• Identification of the breast cancer susceptibility gene BRCA2

  1995cited by this paper
• The Bloom's syndrome gene product is homologous to RecQ helicases.

  1995cited by this paper
• A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

  1994cited by this paper
• BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers.

  1991cited by this paper

• Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile

  2023cites this paper
• Clinicopathologic and genetic analysis of invasive breast carcinomas in women with germline CHEK2 variants

  2023cites this paper
• Somatic loss of the remaining allele occurs approximately in half of CHEK2-driven breast cancers and is accompanied by a border-line increase of chromosomal instability

  2022cites this paper
• HER2-low breast cancer shows a lower immune response compared to HER2-negative cases

  2022cites this paper
• Investigation of monogenic causes of familial breast cancer: data from the BEACCON case-control study

  2021cites this paper
• Population-Based Estimates of the Age-Specific Cumulative Risk of Breast Cancer for Pathogenic Variants in CHEK2: Findings from the Australian Breast Cancer Family Registry

  2021cites this paper
• Population-based estimates of breast cancer risk for carriers of pathogenic variants identified by gene-panel testing

  2021cites this paper
• Genetic Predictors of Malignancy: a Literature Review

  2021cites this paper
• Генетические предикторы развития злокачественных новообразований (обзор литературы)

  2021cites this paper
• Increased gene expression variability in BRCA1-associated and basal-like breast tumours

  2021cites this paper
• Population-based estimates of breast cancer risk for carriers of pathogenic variants identified by gene-panel testing

  2021cites this paper
• CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate

  2020cites this paper
• Hereditary : BRCA and Other

  2020cites this paper
• Genetics and Genomics of Breast Cancer: update and translational perspectives.

  2020cites this paper
• TEffectR: an R package for studying the potential effects of transposable elements on gene expression with linear regression model

  2019cites this paper
• Germline Genetic Testing for Breast Cancer Risk: The Past, Present, and Future.

  2019cites this paper
• Clonality, Antigen Recognition, and Suppression of CD8+ T Cells Differentially Affect Prognosis of Breast Cancer Subtypes

  2019cites this paper
• Absence of the CHEK2 c.1100delC mutation in familial breast and ovarian cancer in Colombia: a case-control study

  2018cites this paper
• Absence of the CHEK 2 c . 1100 delC mutation in familial breast and ovarian cancer in Colombia : a case-control study

  2018cites this paper
• Identification and analysis of CHEK2 germline mutations in Chinese BRCA1/2-negative breast cancer patients

  2018cites this paper
• Transcriptome mining of non‐BRCA1/A2 and BRCA1/A2 familial breast cancer

  2018cites this paper
• Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma

  2017cites this paper
• Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer

  2017cites this paper
• Transcriptional signature of lymphoblastoid cell lines of BRCA1, BRCA2 and non-BRCA1/2 high risk breast cancer families

  2017cites this paper
• Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management.

  2016cites this paper
• Edinburgh Research Explorer Age-and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers

  2016cites this paper
• Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.

  2016cites this paper
• Edinburgh Research Explorer Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers

  2016cites this paper
• Patient survival and tumor characteristics associated with CHEK2:p.I157T – findings from the Breast Cancer Association Consortium

  2016cites this paper
• Proper genomic profiling of (BRCA1‐mutated) basal‐like breast carcinomas requires prior removal of tumor infiltrating lymphocytes

  2015influential citation
• Prognostic value of a mRNA immune infiltrate signature on histopathological breast cancer subtypes of lymph node-negative primary operable breast cancer 4

  2015cites this paper
• Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers

  2015influential citation
• Genotype/Phenotype Correlations in Patients with Hereditary Breast Cancer

  2015cites this paper
• NAIP and CARD-only proteins in inflammasome signaling

  2015cites this paper
• BC patients carrying the germline CHEK 2 1100 delC mutation mainly develop estrogen receptor ( ER )-positive

  2015cites this paper
• Genomic profiling of CHEK2*1100delC-mutated breast carcinomas

  2015cites this paper
• CHEK2 c.1100delC allele is rarely identified in Greek breast cancer cases.

  2015cites this paper
• Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy

  2014cites this paper
• RNA profiling reveals familial aggregation of molecular subtypes in non-BRCA1/2 breast cancer families

  2014cites this paper
• Targeted sequencing by proximity ligation for comprehensive variant detection and local haplotyping

  2014cites this paper
• Hereditary Breast Cancer: Clinical, Pathological and Molecular Characteristics

  2014cites this paper
• CHEK2*1100delC homozygosity in the Netherlands—prevalence and risk of breast and lung cancer

  2013cites this paper
• Emerging Concepts in Breast Cancer Risk Prediction

  2013cites this paper
• Classifications within Molecular Subtypes Enables Identification of BRCA1/BRCA2 Mutation Carriers by RNA Tumor Profiling

  2013cites this paper